Adamax
A designer Semax analog engineered for deeper brain penetration and a dramatically longer receptor-binding window than its parent nootropic.
Adamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) marketed as a next-generation analog of Semax, combining the Semax core sequence with the acetyl/amide caps of P-21 and an adamantane-derived modification intended to improve blood-brain-barrier penetration and metabolic stability. It is reported to upregulate BDNF/TrkB signaling and modulate dopamine D2 receptor sensitivity in motivation circuits, with community protocols citing sustained (~72 hour) receptor effects that permit every-other-day dosing. Note that the name 'Adamax' is used inconsistently across the market: some vendors and directories apply it instead to Davunetide (NAP, NAPVSIPQ), an unrelated ADNP-derived microtubule-stabilizing octapeptide that failed its Phase 2/3 trial for progressive supranuclear palsy.
Class
Synthetic nonapeptide (Semax/P-21 designer analog)
Half-life
~72 hours receptor binding (community-reported); serum half-life uncharacterized
Routes
Subcutaneous, Intranasal
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
BDNF and TrkB upregulation
Adamax is reported to upregulate brain-derived neurotrophic factor expression and boost TrkB receptor sensitivity in hippocampal models. BDNF drives neuronal plasticity, dendritic spine formation, and long-term potentiation, the proposed substrate for its cognitive and mood-stabilizing effects (preclinical/anecdotal).
Dopaminergic D2 modulation
It modulates D2 receptor sensitivity in the ventral tegmental area and nucleus accumbens, the brain's core motivation and reward circuits. This overlaps with Semax's dopaminergic action but is described as more sustained due to the longer receptor binding window.
Improved blood-brain-barrier penetration
The adamantane element, shared with CNS drugs such as amantadine and memantine, is hypothesized to increase the fraction of peripherally administered peptide reaching central targets, so lower nasal or subcutaneous doses may match higher doses of unmodified Semax.
Sustained receptor occupancy
Research protocols cite stable receptor binding across roughly 72 hours post-dose, far longer than intranasal Semax's ~30-60 minute serum half-life, supporting every-other-day or 3x/week schedules rather than multiple daily doses.
Cognitive enhancement and motivation
Community protocols report improved focus, memory consolidation, motivation, and mood stabilization, typically building over the first 1-2 weeks and plateauing at weeks 3-4 (anecdotal, no controlled data).
No reported tolerance at standard cycles
Users report no meaningful tolerance buildup across standard 4-8 week cycles when a 2-week washout is observed between cycles.
Mechanism
How it works
Adamax is a structural derivative of Semax: it retains Semax's Ac-MEHFPGP core, adds an Ala-Gly tail, and applies the N-terminal acetyl and C-terminal amide caps characteristic of the cognitive enhancer P-21, together with an adamantane-derived structural modification. This design is intended to preserve Semax's neurotrophic pharmacology while improving metabolic stability and central bioavailability.
Its primary reported mechanism is upregulation of BDNF expression and enhanced sensitivity of the TrkB receptor, the master regulators of neuronal plasticity and long-term potentiation. In parallel, Adamax is reported to modulate dopamine D2 receptor sensitivity in the ventral tegmental area and nucleus accumbens, the mesolimbic motivation and reward circuits, producing motivation and mood effects that overlap with Semax but are described as longer-lasting.
The adamantane group is the key differentiator. Adamantane appears in several CNS-active drugs (amantadine, memantine) where it confers improved blood-brain-barrier permeability. In Adamax this modification is hypothesized to raise the fraction of injected or intranasal peptide reaching central targets and to extend receptor occupancy to roughly 72 hours, versus the ~30-60 minute serum half-life of intranasal Semax, which is why community protocols favor every-other-day dosing.
Important caveat: primary literature under the name 'Adamax' does not exist as of 2026. Its pharmacology is extrapolated from Semax data and community reports, and its specific receptor-level kinetics, dose-response curves, and long-term safety remain under-characterized. Where the 'Adamax' label is applied to Davunetide/NAP instead, the relevant mechanism is entirely different: microtubule stabilization via an ADNP-derived (NAPVSIPQ) sequence.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Reconstitute the lyophilized peptide with bacteriostatic water at the lowest practical volume to maximize concentration. Example: add 2 mL BAC water to a 5 mg vial to yield 2,500 mcg/mL; on a 100-unit insulin syringe, 10 units = 0.1 mL = 250 mcg. Store the reconstituted vial refrigerated at 2-8 degrees Celsius and use within 28 days. Visually inspect each draw and discard if cloudy or discolored.
Beginner
- Dose
- 500 mcg
- Frequency
- Every other day
- Timing
- Morning or early afternoon (avoid late-day dosing)
- Duration
- 4 weeks
- Route
- Subcutaneous
Start here to assess tolerance and cognitive response before increasing. Week 1 titration point.
Intermediate
- Dose
- 750-1000 mcg
- Frequency
- 3x per week (e.g. Mon/Wed/Fri)
- Timing
- Morning or early afternoon
- Duration
- 6-8 weeks
- Route
- Subcutaneous
Therapeutic dosing range; cycle off for 2 weeks before the next cycle.
Advanced
- Dose
- 1500-2000 mcg
- Frequency
- Every other day
- Timing
- Morning or early afternoon
- Duration
- 8 weeks
- Route
- Subcutaneous
Effects plateau above ~1500 mcg. May be combined with Selank or Dihexa; pause and reassess if irritability or sleep disturbance emerges.
- Typical community dose range is 500-2000 mcg subcutaneous; effects appear to plateau above 2 mg per administration and dosing is not weight-based at these levels.
- Run 4-8 week cycles with at least a 2-week washout between cycles.
- Subcutaneous is the dominant route because the lipophilic adamantyl tail slows nasal absorption; intranasal protocols exist but require higher doses for comparable central effects.
- Daily dosing is generally unnecessary given the reported ~72 hour receptor binding, and may increase risk of D2 desensitization without proportionate benefit.
- Store lyophilized peptide at -20 degrees Celsius desiccated; store reconstituted vials at 2-8 degrees Celsius and use within 28 days.
Evidence
Research & clinical studies (2)
Davunetide (AL-108) Phase 2/3 trial in progressive supranuclear palsy
The Allon Therapeutics Phase 2/3 trial of Davunetide (NAP) in PSP failed to meet its primary efficacy endpoint, leading to program discontinuation, though safety was favorable (mild injection-site reactions and transient headache, no significant serious adverse event signals). This pertains to the Davunetide compound sometimes marketed under the 'Adamax' name, not the Semax analog.
Davunetide Phase 2 trial in mild cognitive impairment
Earlier Phase 2 work with Davunetide/NAP in mild cognitive impairment also produced disappointing efficacy results despite mechanistically interesting microtubule-stabilizing activity in preclinical models.
Combinations
Stacking & blends
Adamax + Selank
Mood stabilization with motivation and cognition
Selank's GABAergic/serotonergic anxiolytic profile is complementary rather than overlapping with Adamax's BDNF/D2 mechanism, making this the most common and lowest-interaction-risk pairing.
Adamax + Dihexa
Memory-focused enhancement
Dihexa's angiotensin-IV-derived synaptogenic effects pair with Adamax's BDNF/TrkB upregulation for memory-consolidation protocols.
Adamax + BPC-157
Neuroprotective cognitive baseline
BPC-157 provides a neuroprotective, dopaminergic-stabilizing baseline that pairs well with cognitive enhancers.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Not approved for human use by any regulatory agency
- Pregnancy and breastfeeding (no safety data)
- History of bipolar disorder or psychosis (dopaminergic modulation)
- Concurrent dopaminergic medications (e.g. Wellbutrin, Adderall, MAOIs) without clinician oversight
- Simultaneous full-dose stacking with Semax or P-21 (overlapping receptor systems, risk of desensitization)
- Uncontrolled hypertension; no safety data in active malignancy, autoimmune, or seizure disorders
Safety data is limited because no formal clinical trials of the Semax-analog Adamax exist; side-effect reports are anecdotal and resemble Semax's profile. No serious adverse events have been published, but this reflects underreporting in unregulated use rather than formal safety clearance. Individual response variability is high.
FAQ
Adamax — common questions
Is Adamax just Semax with a chemistry tweak?
Essentially yes in kind, but different in duration. It is Semax's Ac-MEHFPGP core plus an Ala-Gly tail and P-21-style acetyl/amide caps, with an adamantyl modification. The primary mechanism (BDNF/TrkB/D2 modulation) is the same, but the adamantane group is hypothesized to improve blood-brain-barrier penetration and extend receptor binding to roughly 72 hours versus Semax's ~30-60 minute serum half-life.
Why are there no PubMed studies for Adamax?
Adamax was first synthesized by a research-peptide vendor (Ceretropic) around 2016, not by the Russian Institute of Molecular Genetics that developed Semax and Selank, so it never entered the formal academic publication pipeline. Its effects are extrapolated from Semax data and community reports; no primary literature under the 'Adamax' name exists as of 2026.
Why does some information describe Adamax as Davunetide?
The name 'Adamax' is used inconsistently in the market. Some vendors and directories apply it to Davunetide (NAP, NAPVSIPQ), an unrelated ADNP-derived microtubule-stabilizing octapeptide that reached Phase 2/3 trials for progressive supranuclear palsy and failed its primary endpoint. That is a different molecule with a different mechanism from the Semax-analog Adamax; verify exactly which compound a vendor is selling.
Intranasal or subcutaneous, which route do most researchers use?
Both are documented, but subcutaneous is more common. The adamantyl tail makes the molecule larger and more lipophilic than parent Semax, which slows nasal absorption, so intranasal protocols require higher doses. Subcutaneous at 500-1500 mcg every other day is the dominant community pattern.
How does the dosing schedule differ from Semax?
Semax is typically dosed daily, often several times a day, because of its short serum half-life. Adamax protocols cite stable receptor occupancy across ~72 hours, supporting every-other-day or 3x/week dosing. Daily dosing is generally unnecessary and may increase D2 desensitization risk without added benefit.
Can Adamax be stacked with Semax or P-21?
With caution. All three modulate overlapping BDNF/TrkB/D2 systems, and simultaneous full-dose stacking is uncharacterized and risks additive receptor desensitization. Adamax + Selank is a more common pairing because those mechanisms are complementary rather than overlapping.
What does a full Adamax cycle look like?
A typical research cycle is 4-8 weeks with at least a 2-week washout. Beginners start at 500 mcg subcutaneous every other day, intermediate users move to 750-1000 mcg three times per week, and advanced protocols cap around 1500-2000 mcg every other day. Effects build over the first 1-2 weeks and plateau around weeks 3-4.
Are there safety red flags?
There are no formal toxicology studies. Anecdotal reports cite mild, mostly dose-related side effects similar to Semax: headache, transient insomnia if dosed in the evening, and occasional irritability. Avoid during pregnancy, lactation, active psychiatric instability, and uncontrolled hypertension.
